Mission
	Management
	History

Jomaa Pharma GmbH is developing a novel treatment for malaria. This is based on a combination of two drugs that inhibit a recently identified chemotherapeutic target in the parasite and which have already been administered to man.

Jomaa Pharma GmbH owns the commercial rights to this new drug combination. Fosmidomycin™, that represents a novel cutting-edge pharmaceutical approach to cure malaria caused by Plasmodium falciparum, is presently being studied in clinical trials in Africa and Asia. The orally administered combination product has been shown to be effective and well tolerated making it a low risk drug with high cure rates for the treatment of malaria in children and adults.

Jomaa Pharma GmbH was founded in January 2003 by BioAgency AG as a privately owned registered limited company with premises in Hamburg, Germany, and Westerham, United Kingdom.